ArticleGynecologic oncology reports2026
Paraneoplastic pemphigus in primary peritoneal clear cell carcinoma: a multidisciplinary management approach.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paraneoplastic pemphigus (PNP) or paraneoplastic autoimmune multiorgan syndrome (PAMS) is a rare, mucocutaneous blistering condition associated with high morbidity and mortality. Most reported cases occur in the setting of lymphoproliferative malignancies, with limited data describing associations with solid tumors. Additionally, standardized diagnostic criteria and management guidelines remain lacking. We describe the first, to our knowledge, case of PNP/PAMS associated with primary peritoneal clear cell carcinoma. Case Presentation: A 47-year-old woman with recurrent, platinum-resistant primary peritoneal clear cell carcinoma presented with painful oral mucosal erosions, intermittent epistaxis, and a pruritic cutaneous eruption involving the trunk, groin, and lower extremities approximately four weeks after her fourth cycle of gemcitabine, cisplatin, and bevacizumab. Skin punch biopsy, serologies, and clinical findings were consistent with PNP/PAMS. She was treated with high-dose intravenous corticosteroids, followed by multiple adjunctive systemic and supportive therapies through a multidisciplinary approach; however, her recalcitrant and aggressive mucocutaneous disease progressed, contributing to significant clinical decline. She ultimately transitioned to comfort-focused care and died from complications of her underlying malignancy. Conclusion: This case highlights the diagnostic and therapeutic challenges of PNP/PAMS in patients with solid tumors and underscores the importance of multidisciplinary management in the absence of standardized treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.